{
  "ticker": "TYP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960866",
  "id": "02960866",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250623",
  "time": "0933",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l02jhr7snz67.pdf",
  "summary": "- **Ethics approval received** for open-label study of TRP-8803 (IV-infused psilocin) in Binge Eating Disorder (BED).  \n- **Trial details**: 12 patients, two doses 14 days apart, first dosing expected in **Q3 CY25**, top-line results in **Q4 CY25**.  \n- **Market relevance**: BED is the most common eating disorder in the US and second in Australia, with high unmet need.  \n- **Secondary focus**: Trial may provide data on TRP-8803\u2019s impact on comorbidities (depression, anxiety, PTSD).  \n- **Previous data**: Phase 2a oral psilocybin (TRP-8802) showed >80% reduction in Binge Eating Scores.  \n\n*No capital markets/trading actions (e.g., raising, halt) or financial metrics disclosed.*",
  "usage": {
    "prompt_tokens": 3101,
    "completion_tokens": 183,
    "total_tokens": 3284,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-22T23:39:13.774290"
}